EZH2 accompanies prostate cancer progression

Enhancer of zeste homolog 2 (EZH2) has been shown to promote development of castration-resistant prostate cancer (CRPC) through various mechanisms. A new study now shows that a phosphorylated EZH2 interacts with the androgen receptor (AR) and reprograms AR transcriptional activity to facilitate transition of CRPC into a lineage infidelity state.